Mergers & Acquisitions
By The Online Investor Staff, updated Tue., Apr. 23, 8:18 PM
Slide #76. Vertex Pharmaceuticals Incorporated — Alpine Immune Sciences, Inc.
Acquirer: |
Vertex Pharmaceuticals Incorporated (VRTX) |
Acquiree: |
Alpine Immune Sciences, Inc. (ALPN) |
Details: |
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter. |
Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
Vertex Pharmaceuticals SEC Filing Email Alerts Service
Open the VRTX Page at The Online Investor » Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
Vertex Pharmaceuticals SEC Filing Email Alerts Service
Open the ALPN Page at The Online Investor »
Company Name: |
Vertex Pharmaceuticals, Inc. |
Stock buyback: |
VRTX buyback |
Website: |
www.vrtx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding VRTX: |
124 |
Total Market Value Held by ETFs: |
$15.38B |
Total Market Capitalization: |
$101.85B |
% of Market Cap. Held by ETFs: |
15.10% |
|
Company Name: |
Alpine Immune Sciences Inc |
Website: |
www.alpineimmunesciences.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding ALPN: |
30 |
Total Market Value Held by ETFs: |
$414.82M |
Total Market Capitalization: |
$4.23B |
% of Market Cap. Held by ETFs: |
9.80% |
|
|
April 23, 2024 8:18 PM Eastern
|